Trial Profile

A Double-Arm, Open Label, Phase III Study to Compare the Efficacy and Safety of SCENESSE and Narrow-Band Ultraviolet B (NB-UVB) Light Versus NB-UVB Light Alone in the Treatment of Vitiligo

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 06 Nov 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

19 Sep 2025 According to a Clinuvel Pharmaceuticals Media Release, company e look forward to learning the full study results in 2026.
19 Sep 2025 According to a Clinuvel Pharmaceuticals Media Release, The three patients treated at a single reference hospital in La Reunion, France, all completed treatment in CLINUVEL's ongoing CUV105 study, receiving seven SCENESSE implants and up to 40 narrowband ultraviolet B (NB-UVB) phototherapy sessions.
19 Sep 2025 According to a Clinuvel Pharmaceuticals Media Release, case efficacy data from this study presented to the European Academy of Dermatology and Venereology (EADV) conferencein Paris, France.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com